Numerate and the Gladstone Institute have licensed their novel ApoE4 drug program to a stealth biotechnology company with whom they will continue to work to push the program forward. Financial terms of the agreement were not disclosed. As details are made public by the stealth biotech and its investors, we will update the story.
This is an example of what the Numerate platform can do to translate early stage programs with exciting emerging biology into valuable assets worth advancing, as quickly as possible, towards the clinic. Despite the intrinsic difficulty of designing structure correctors, we were able to generate valuable ApoE4 assets in a matter of months and with only the money from our Wellcome Trust contract. We are unaware of any other approach (computational or non) that could have produced these results.